Overview
My research is broadly focused on elucidating the complex interactions that exist between the host microbiome and exogenous pathogens that cause infections in children. We have several ongoing projects evaluating: 1) the impact of the upper respiratory microbiome on the risk of colonization and invasion by bacterial respiratory pathogens among infants in Botswana; 2) associations between the gut microbiome of pediatric stem cell transplant recipients and the risk of infections (bloodstream infection, C. difficile infection) and graft-versus-host disease; and 3) the role of the gut and respiratory microbiomes in mediating COVID-19 infection susceptibility and disease severity in children. Ultimately, I aim to develop strategies that use targeted modification of the microbiome for the prevention of infections in children.
Current Appointments & Affiliations
Adjunct Associate Professor of Pediatrics
·
2025 - Present
Pediatrics, Infectious Diseases,
Pediatrics
Member of the Human Vaccine Institute
·
2024 - Present
Duke Human Vaccine Institute,
Institutes and Centers
Recent Publications
Global Assessment of Health Utilities Associated with Pneumococcal Disease in Adults: Targeted Literature Reviews.
Journal Article Pharmacoecon Open · December 10, 2025 BACKGROUND: Pneumococcal disease can significantly reduce quality of life (QoL). Health utilities are commonly used to assess QoL burden and calculate quality-adjusted life years (QALYs), which are critical inputs in cost-utility analyses (CUAs) to evaluat ... Full text Link to item CiteComprehensive Assessment of the Intrinsic Pancreatic Microbiome.
Journal Article Ann Surg · December 1, 2025 OBJECTIVE: To sought comprehensively profile tissue and cyst fluid in patients with benign, precancerous, and cancerous conditions of the pancreas to characterize the intrinsic pancreatic microbiome. BACKGROUND: Small studies in pancreatic ductal adenocarc ... Full text Link to item CiteReal-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.
Journal Article Blood Adv · November 11, 2025 Tisagenlecleucel (tisa-cel) is a CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory precursor B-cell acute lymphoblastic leukemia (R/R B-ALL). We report infectious complications for 100 days (D100) following tisa-cel therapy in ... Full text Link to item CiteRecent Grants
Role of C difficile Colonization in Risk of Disease
ResearchCo-Mentor · Awarded by National Institutes of Health · 2025 - 2030The Gut Microbiome and Development of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation in Children
ResearchMentor · Awarded by National Institutes of Health · 2025 - 2030Unified Program for Therapeutics in Children
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030View All Grants
Education, Training & Certifications
Harvard Medical School ·
2007
M.D.
Harvard University ·
2007
M.P.H.